Embed Size (px)
Citation preview
1
Bionest Oncology Capabilities
2016
Bionest Oncology Capabilities2016 – Slide 2
Significant Transformation in the Oncology Market
Novel technologies and treatment approaches are changing oncology drug development and commercialization strategies. Companies need to adapt in an
increasingly complex environment.
ONCONext
GENE & PROTEIN SIGNATURES
COMBINATION STRATEGY
IMMUNO-ONCOLOGY
BIG DATA COLLECTIONINCREASING SEGMENTATION
INNOVATIVE TRIAL DESIGN
QoL vs. SURVIVAL
PAYER PATHWAYS
NEXT-GENERATION TECHNOLOGY
COMPANION Dx
COMPANION DRUG TUMOR AGNOSTIC STRATEGY
BIOMARKER DRIVEN LCM
PATIENT CENTRIC STRATEGY
LONGITUDINAL TESTINGADVOCACY STRATEGY
Bionest Oncology Capabilities2016 – Slide 3
= Global Actionable Strategies for Life Sciences
Global reachOffices across North
America, Europe, Asia and activities across all 5
continents
Pharma and DxLeading expertise in
diagnostics and personalized medicine
Actionable StrategiesEmphasis on helping decision making through cross-
functional collaborative approaches and “Implementation Ready” strategies
Bionest Oncology Capabilities2016 – Slide 4
Europe
Rachel LaingManagerBasel
Anne-Sophie DemangeManagerParis
Alain GilbertCo-ChairmanParis
Asia
Yasuhiro Komatsu
Senior Advisor
Tokyo
Additional Strategic partner in China
America
Mary KotoFounderSan Diego
Olivier LesueurManaging DirectorNew York
Bob EastonCo-ChairmanNew York
Additional Strategic partner in South America
Bionest is a global consulting firm with an experienced management team
Bionest Oncology Capabilities2016 – Slide 5
We Support Innovation Across Key Development and Commercialization Challenges in Oncology
Build a High-Value Portfolio
Where to play?
Breakthrough technology or tumor area strategy
Corporate development strategy
Search and scout
How to place the bets?
Portfolio strategy
Valuation and risk analysis
Asset / company due diligence
Optimize Brand Development Strategy
Prepare for Commercial Success
Where are the opportunities?
In-depth disease landscape
Opportunity mapping, initial segmentation and TPP testing
What is needed to win?
Customer Journey and key intervention points
Innovative competitive differentiation strategies
What development strategy?
Value of innovative strategies – e.g., combination, biomarker strategies
How to differentiate?
Competitive Simulations
Qual. / Quant. Positioning
Brand strategic planning
Customer services / Advocacy
How to maximize value?
Life cycle strategy
How to Commercialize?
Innovative commercial models
EU / WW market entry
Drug / Dx commercialization
Bionest Oncology Capabilities2016 – Slide 6
What external opportunities should we consider for our Hem-Onc portfolio?
Strategic review of the hem-onc landscape
Identified and prioritized acquisition targets
Trade-off analysis, watch list, and recommendations for the BD team
What immunotherapy combination strategy
for our targeted oncology portfolio?
Assessment of potential immunotherapy partners
Mapping of opportunity areas where combination(s) would drive value
Recommendation on partner and deal strategy
What is the opportunity for our novel TKI in gastric
cancer?
Gastric cancer market review: US, EU, and Japan
TPP testing and discussion around efficacy thresholds
Opportunity segments and recommendation on gastric cancer development strategy
Bionest Has Helped its Clients Tackle Key Oncology Business Questions
Which oncology indication(s) should we prioritize for our
asset?
Full market assessment of indications in question
TPP testing and evaluation of potential opportunity
Assessment of strategic options and scenario planning to prepare for upcoming decision making
What LCM strategy for my asset in NSCLC?
Comprehensive assessment of NSCLC landscape
Recommendation on priority opportunities to consider
Key guidelines for commercialization, including biomarker / CDx strategy
What positioning strategy for our breast
cancer asset?
Deep qualitative analysis of breast cancer landscape
Positioning workshop/competitive simulation
Quantitative testing of share preference/source of business by scenario and recommendation
PO
RTFO
LIO
BR
AN
D
DEV
ELO
PM
EN
TC
OM
MER
CIA
L
SU
CC
ES
S
Bionest Oncology Capabilities2016 – Slide 7
Bionest has a Strong Track Record in OncologyExtensive Thought Leadership
“Immunotherapy: Big Pharma’s Seductive Embrace”
IN VIVO, Dec. 2014
“Companies are…setting up combination trials early in
clinical development…This notion of seeking synergy from
the get-go is a dramatic shift in how cancer drugs are
developed, with strong implications for partnering, pricing,
and life cycle management”
SEPTEMBER 2015
“Immuno-Oncology Brings New
Opportunities for Developers of
Targeted Cytotoxics”
Personalized Medicine in Oncology
Selected Articles and Presentations
To read these articles and more, visit http://bionest.com/publications/publications/
2016
“Time to be Savvy for
Next-Generation
Immuno-oncology”
Article in Progress
2016
“Can CDx Save the Next-
Generation of Immuno-
Oncology?”
Article in Progress
First-generation IO agents have, for the most part, been widely approved. After the
focus on precision medicine for molecular therapies, it has
failed to make its way into IO thus far. However, the IO space is poised to become increasingly
complex. Experts recognize that biomarker approaches will become increasingly important, but how this will play out and who will drive this remains to
be seen.
Opdivo and Keytruda have been approved and incorporated into
standard-of-care in several indications, with other
approvals on the horizon. Companies are capitalizing on
immuno-oncology’s (IO) success, pushing forward with
additional PD-1/L1 inhibitors as well as next-generation
therapies. These companies face a highly competitive and
complex market, where past strategies may prove obsolete and more savvy bets may drive
success.
Bionest Oncology Capabilities2016 – Slide 8
We Support Decision Making for the Following Clients
Selected Clients
Bionest Oncology Capabilities2016 – Slide 9 9 9
19, rue du Général Foy75008 Paris
France
Tel: +33 1 58 05 14 00
380 Lexington Ave, 43rd FloorNew York, NY 10168
USA
Tel: +1 612 212 3030
www.bionest.com
